Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 5/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 5/20 | 0.42 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13183603 | 0.87 | HSD17B1 (0.44) | HSD17B1HSD17B2SLC6A7CYP3A4CYP2C9 | |
| SCHEMBL10472855 | 0.86 | HSD17B1 (0.47) | HSD17B1HSD17B2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL695227 | 0.84 | SLC6A7 (0.41) | HSD17B1HSD17B2SLC6A7CYP3A4CYP2C9 | |
| SCHEMBL18516556 | 0.82 | ACHE (0.47) | HSD17B1HSD17B2SLC6A7CYP3A4CYP2D6 | |
| SCHEMBL7567903 | 0.81 | PTGS2 (0.34) | ARSLC6A7SREBF2DAOCYP2A6 | |
| SCHEMBL51899 | 0.80 | SLC6A7 (0.50) | HSD17B1HSD17B2SLC6A7CNR1LMNA | |
| SCHEMBL19112124 | 0.79 | HSD17B1 (0.54) | HSD17B1HSD17B2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL18699241 | 0.79 | HSD17B1 (0.39) | HSD17B1HSD17B2SLC6A7CYP3A4CYP2D6 | |
| SCHEMBL17715743 | 0.79 | BCL2 (0.41) | HSD17B1HSD17B2SLC6A7CYP3A4CYP2D6 | |
| SCHEMBL1521848 | 0.78 | SLC6A7 (0.36) | HSD17B1HSD17B2SLC6A7CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112018254-B | Quantum dot light-emitting diode based on phenylthiol derivative and preparation method thereof | 河南工程学院 | 2023-09-19 | — | — | CN | claimed |
| WO-2025242668-A1 | SWITCHABLE CAPSULE-LUMINESCENT PIGMENTS | GIESECKE+DEVRIENT CURRENCY TECHNOLOGY GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025242650-A1 | SWITCHABLE ENCAPSULATED LUMINESCENT PIGMENTS | GIESECKE+DEVRIENT CURRENCY TECHNOLOGY GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| US-11667630-B2 | Nitrogen-containing 6-membered cyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-06-06 | — | — | US | disclosed |
| EP-4140485-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-3356344-B1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LTD (GB) | 2022-11-16 | — | — | EP | disclosed |
| US-20220106287-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2022-04-07 | — | — | US | disclosed |
| US-11261171-B1 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2022-03-01 | — | — | US | disclosed |
| US-11193065-B2 | Liquid crystal composition, method of producing the same, and retardation film constituted from the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-12-07 | — | — | US | disclosed |
| EP-3848375-A1 | METHODS OF PREPARING INTERMEDIATES FOR TOLL-LIKE RECEPTOR MODULATORS | Gilead Sciences, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-7612108-B2 | Such as 5-(3-cyano-4-n-propoxyphenyl)thiophene-2-carboxylic acid; for diseases associated with xanthine oxidase such as hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy | ASTELLAS PHARMA INC. (JP) | 2009-11-03 | — | — | US | disclosed |
| WO-2008081282-A2 | PROCESS FOR THE SYNTHESIS OF N9-(3,5-DICHLORO-4-PYRIDYL)-6- DIFLUOROMETHOXYBENZO(4,5)FURO(3,2-C)PYRIDINE-9-CARBOXAMIDE AND SALTS THEREOF | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008061029-A1 | ARYL SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080027048-A1 | Such as 5-(3-cyano-4-n-propoxyphenyl)thiophene-2-carboxylic acid; for diseases associated with xanthine oxidase such as hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy | ASTELLAS PHARMA INC. (JP) | 2008-01-31 | — | — | US | disclosed |
| EP-1831227-A2 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | Glenmark Pharmaceuticals S.A. (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006064355-A2 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | GLENMARK PHARMACEUTICALS S.A. (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006040650-A1 | 4-METHOXYACRIDINE-1-CARBOXAMIDE DERIVATIVES AND THE PHENAZINE AND OXANTHRENE ANALOGS AS PDE4-INHIBITORS FOR THE TREATMENT OF ASTHMA AND CHRONIC PULMONARY DISEASE (COPD) | GLENMARK PHARMACEUTICALS S.A. (US) | 2006-04-20 | — | — | WO | disclosed |
| CN-1026234-C | Thiazolidinedione derivatives for lowering blood glucose | PFIZER (US) | 1994-10-19 | — | — | CN | disclosed |
| EP-0078668-A1 | Preparation of aminocyclopentanealkenoic acids | GLAXO GROUP LIMITED (GB) | 1983-05-11 | — | — | EP | disclosed |
| US-4327092-A | USEFUL AS ANTICOAGULANTS AND ANTI-HISTAMINES | GLAXO GROUP LIMITED (GB) | 1982-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106287-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | AR 891/4885HSD17B1 925/4885HSD17B2 1365/4885 |
| US-20080027048-A1 | Such as 5-(3-cyano-4-n-propoxyphenyl)thiophene-2-carboxylic acid; for diseases associated with xanthine oxidase such as hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy | XDH, UACA, NUDT1 | AR 4192/4885HSD17B1 1201/4885HSD17B2 1680/4885 |
| US-11261171-B1 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | TP53, MDM2, TP53BP1 | AR 891/4885HSD17B1 925/4885HSD17B2 1365/4885 |
| US-11667630-B2 | Nitrogen-containing 6-membered cyclic compound | PTGER4, EPB41, BMP4 | AR 521/4885HSD17B1 3029/4885HSD17B2 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.